Drugs / Intranasal Insulin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06072963 | Jan 2024 → Dec 2027 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia, metabolic syndrome X | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00314314 | May 2006 → Mar 2009 | bipolar disorder | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intranasal Insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00314314 ↗ |
| Route | Intranasal | “Intranasal spray; 40 IU qid; 8 weeks” NCT00314314 ↗ |